Just Gene Therapy is a not for profit organisation established to raise funds for gene therapy for cystic fibrosis.

Imperial College London

Alongside Professor Eric Alton, the representatives of the UK CF Gene Therapy Consortium Strategy Group from Imperial College London are:

Dr Jane Davies

Dr Jane Davies graduated MB ChB from the University of Dundee Medical School in 1987 and undertook clinical training in Paediatrics in London. A post at the Royal Brompton Hospital led to an interest in cystic fibrosis (CF), particularly host-pathogen interactions and her MD focussed on the pathogenesis of Pseudomonas aeruginosa in the lung. Her clinical training was subsequently completed at Great Ormond Street Hospital in the departments of Respiratory Medicine and Infectious Diseases / Immunology. She returned to Imperial College London in 1999, as a Senior Lecturer and is now a Reader in Paediatric Respiratory Medicine & Gene Therapy.

Jane is the clinical lead for the London arm of the Consortium.  She is heavily involved in clinical trial design and the validation of outcome measures such as lung clearance index and sputum inflammatory markers. On the consortium trials she conducts the bronchoscopic assays and leads on the electrophysiological measurements (potential difference) both in the nose and lower airway.

Jane is also an Honorary Consultant in Paediatric Respiratory Medicine at the Royal Brompton and Harefield NHS Foundation Trust.

Dr Uta Griesenbach

Dr Uta Griesenbach is a Reader in Molecular Medicine at Imperial College London. She joined the Department of Gene Therapy, National Heart & Lung Institute, in 1997 having earlier graduated from the University of Bonn (Germany) with a First Class degree in Diploma Biology and having completed a PhD degree at the Hospital for Sick Children, Toronto, Canada with Prof Lap-Chee Tsui.

Since joining the Consortium, Uta's research has focussed on gene therapy, mainly but not exclusively related to CF. As part of this work she has gained substantial experience in viral and non-viral in vivo gene transfer to lung and myocardium. In collaboration with DNAVEC Coporation (a Japanese Biotech company) Uta has been responsible for the development of a lentiviral vector, specifically designed to transduce airway epithelial cells. This vector shows great promise in pre-clinical studies and has been selected to be the Consortium's leading "Wave 2" product.

Uta's involvement in the UK CF Gene Therapy Connsortium's clinical trial programme includes overseeing toxicology and vector production, as well as the assessment of novel biomarkers.

Ms Tracy Higgins

Miss Tracy Higgins is the Project Manager for the Consortium. She trained as an Administration Manager for Sainsbury's Supermarkets, where from the age of 25 she was running her own department overseeing ordering, price control and financial management. In 2000 Tracy joined Imperial College London as the Laboratory Manager for the Gene Therapy Group, becoming the Consortium's Project Manager in 2006. Tracy is responsible for the logistics of the Consortium. This includes managing multi-site contract negotiations, overseeing the £30M budget, reviewing regulatory paperwork and establishing processes to ensure the Consortium has the resources to deliver its programme.

Tracy is also the Manager of the Respiratory Biomedical Research Unit at the Royal Brompton Hospital.

 

 

 

 

Dr Jane Davies

 

 

Dr Uta Griesenbach

 

 

 

 

 

 

Tracy Higgins
© Just Gene Therapy 2012-14 | Just Gene Therapy is raising money on behalf of Imperial College, an exempt charity*.